--- title: "Cagrilintide | PepTracker Pro" url: https://peptrackerpro.com/peptides/cagrilintide description: "A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Cagrilintide High Evidence A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026. Aliases NN9838 +1 more Evidence High Evidence Last Updated 2026-06-13 Reading Time 3 min ## What It Is Cagrilintide is a long-acting analog of the hormone amylin, which is naturally co-secreted with insulin from pancreatic beta cells. It works by slowing gastric emptying, promoting satiety, and reducing glucagon secretion. It is the amylin component of CagriSema, a once-weekly fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg. On December 18, 2025, Novo Nordisk submitted a New Drug Application (NDA) to the FDA for CagriSema for chronic weight management — making it the first GLP-1/amylin combination to reach NDA stage. Both pivotal Phase 3 trials were published in the New England Journal of Medicine in 2026. In REDEFINE-1, CagriSema achieved 20.4% mean weight loss at 68 weeks, with 60% of participants losing ≥20% and 23% losing ≥30% body weight. In REDEFINE-2 (adults with obesity and T2D), CagriSema achieved 13.7% mean weight loss and 73.5% of participants reached HbA1c ≤6.5% vs 15.9% with placebo. Gastrointestinal AEs affected 79.6% of the CagriSema group but were mostly transient and mild-to-moderate. CagriSema initially fell short of an internal 25% weight loss target, which briefly pressured Novo Nordisk's stock price, though the 22.7% on-treatment weight loss still exceeds most competitors. The FDA is expected to render a decision by approximately October 2026 under standard review timelines. In April 2026, Novo Nordisk announced positive headline results from REIMAGINE-2, a Phase 3 trial in adults with overweight or obesity and type 2 diabetes. CagriSema 2.4 mg/2.4 mg demonstrated superior HbA1c reduction of 1.91 percentage points versus 1.76 with semaglutide 2.4 mg alone (from a baseline of 8.2%), and superior weight loss of 14.2% versus 10.2% with semaglutide alone (from a baseline of ~101 kg) at 68 weeks. These results confirm CagriSema's incremental benefit over its GLP-1 component alone in the T2D population. Also known as: NN9838, CagriSema component ## Proposed Mechanisms - Activates amylin receptors in the area postrema to reduce appetite and caloric intake - Slows gastric emptying, prolonging post-meal satiety signals - Reduces post-prandial glucagon secretion, improving glycemic control - Complements GLP-1 agonism through an independent anorexigenic pathway - Long-acting albumin-binding design extends half-life to once-weekly dosing ## Evidence Snapshot High Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Human (Phase 3) | REDEFINE-1: Adults with obesity, no T2D (n=3,417) | 20.4% mean weight loss at 68 weeks vs 3.0% placebo | Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2502081 | | Human (Phase 3) | REDEFINE-2: Adults with obesity + T2D (n=1,507) | 13.7% mean weight loss at 68 weeks vs 3.4% placebo | Source: https://www.nejm.org/doi/full/10.1056/NEJMoa2502082 | | Human (Phase 2) | Healthy adults with overweight/obesity | Dose-dependent weight loss, well-tolerated GI side effects | Source: https://pubmed.ncbi.nlm.nih.gov/ | ## Commonly Discussed Benefits Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Researching Cagrilintide? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=cagrilintide) ## Safety & Cautions - NDA filed December 2025; FDA decision expected ~October 2026 - Gastrointestinal side effects observed in 79.6% of CagriSema group (mostly mild-to-moderate and transient) - Missed internal 25% weight loss target in REDEFINE-1 — achieved 22.7% on-treatment - Primarily studied in combination with semaglutide, not as standalone - Not yet FDA-approved - Context (June 2026): interest in lean-mass-sparing weight loss is widening beyond amylin agonists. A small early-stage trial of the endocannabinoid-system peptide Pep19 reported visceral-fat reduction without lean-mass loss — a different mechanism worth distinguishing from amylin-based approaches like cagrilintide. ## Comparisons See how Cagrilintide compares to related peptides: Cagrilintide vs ALV-200: https://peptrackerpro.com/compare/cagrilintide-vs-alv-200 Cagrilintide vs ASC39: https://peptrackerpro.com/compare/cagrilintide-vs-asc39 Cagrilintide vs CagriSema: https://peptrackerpro.com/compare/cagrilintide-vs-cagrisema Cagrilintide vs Maridebart Cafraglutide (MariTide): https://peptrackerpro.com/compare/cagrilintide-vs-maridebart-cafraglutide Cagrilintide vs MET-233i: https://peptrackerpro.com/compare/cagrilintide-vs-met-233i Cagrilintide vs Pep19: https://peptrackerpro.com/compare/cagrilintide-vs-pep19 Cagrilintide vs Semaglutide: https://peptrackerpro.com/compare/cagrilintide-vs-semaglutide Cagrilintide vs Survodutide: https://peptrackerpro.com/compare/cagrilintide-vs-survodutide Cagrilintide vs Tirzepatide: https://peptrackerpro.com/compare/cagrilintide-vs-tirzepatide ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Novo Nordisk — CagriSema NDA filing announcement. December 2025 PubMed (https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-302645862.html) 2. [2] REDEFINE-1 — Cagrilintide-Semaglutide in Adults with Overweight or Obesity, NEJM 2026 PubMed (https://www.nejm.org/doi/full/10.1056/NEJMoa2502081) 3. [3] REDEFINE-2 — Cagrilintide-Semaglutide in Adults with T2D, NEJM 2026 PubMed (https://www.nejm.org/doi/full/10.1056/NEJMoa2502082) 4. [4] Novo Nordisk submits NDA for CagriSema — PharmExec, April 2026 PubMed (https://www.pharmexec.com/view/novo-nordisk-submits-nda-fda-cagrisema) 5. [5] Novo Nordisk — REIMAGINE-2 Phase 3 headline results, April 2026 PubMed (https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916481) ### Keep researching in the app - Log Cagrilintide to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=cagrilintide Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### ALV-200 Low Evidence ALV-200 is Alveus Therapeutics' highly selective amylin receptor 3 (AMYR3) peptide agonist in IND-enabling development for obesity, designed to capture amylin's weight-loss and lean-mass-preserving benefits while avoiding the nausea and aversion tied to calcitonin-receptor activation. It is engineered for once-weekly dosing. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Muscle Preservation: https://peptrackerpro.com/benefits/muscle-preservation View Details: https://peptrackerpro.com/peptides/alv-200 \+ Compare: https://peptrackerpro.com/compare?select=alv-200 Track in App: https://app.peptrackerpro.com/?add=alv-200 ### ASC39 Low Evidence ASC39 is Ascletis Pharma's investigational once-daily oral small-molecule amylin-selective amylin receptor agonist for obesity. In head-to-head preclinical assays it matched Eli Lilly's injectable peptide eloralintide on amylin-receptor potency, selectivity over the calcitonin receptor, and weight loss in diet-induced obese rats. Ascletis plans to file a U.S. FDA IND for ASC39 - and for a fixed-dose combination with its oral GLP-1 agonist ASC30 - in the third quarter of 2026. View Details: https://peptrackerpro.com/peptides/asc39 \+ Compare: https://peptrackerpro.com/compare?select=asc39 Track in App: https://app.peptrackerpro.com/?add=asc39 ### CagriSema High Evidence A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) studied for enhanced weight loss through dual hormonal pathways. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/cagrisema \+ Compare: https://peptrackerpro.com/compare?select=cagrisema Track in App: https://app.peptrackerpro.com/?add=cagrisema ### Maridebart Cafraglutide (MariTide) Medium Evidence Amgen's once-monthly injectable GIP receptor antagonist and GLP-1 receptor agonist, showing up to 20% weight loss in phase 2 trials with a unique mechanism that blocks GIP while activating GLP-1. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/maridebart-cafraglutide \+ Compare: https://peptrackerpro.com/compare?select=maridebart-cafraglutide Track in App: https://app.peptrackerpro.com/?add=maridebart-cafraglutide ### MET-233i Medium Evidence MET-233i is a first-in-class, once-monthly ultra-long-acting amylin analog for obesity, originally developed by Metsera and now a Pfizer asset. In its Phase 1 trial it produced up to 8.4% placebo-subtracted weight loss after five weekly doses and showed a roughly 19-day half-life - the most durable of any reported amylin analog - supporting once-monthly subcutaneous dosing. It is engineered to be combined with Metsera's monthly GLP-1 agonist MET-097i in a single once-monthly injection. View Details: https://peptrackerpro.com/peptides/met-233i \+ Compare: https://peptrackerpro.com/compare?select=met-233i Track in App: https://app.peptrackerpro.com/?add=met-233i ### Pep19 Low Evidence An orally dosed synthetic intracellular peptide that acts on the endocannabinoid system; an early human trial showed reduced visceral fat and improved sleep without lean-mass loss. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Metabolism: https://peptrackerpro.com/benefits/metabolism Sleep: https://peptrackerpro.com/benefits/sleep View Details: https://peptrackerpro.com/peptides/pep19 \+ Compare: https://peptrackerpro.com/compare?select=pep19 Track in App: https://app.peptrackerpro.com/?add=pep19 ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+3 more View Details: https://peptrackerpro.com/peptides/semaglutide \+ Compare: https://peptrackerpro.com/compare?select=semaglutide Track in App: https://app.peptrackerpro.com/?add=semaglutide ### Survodutide Medium Evidence A dual GLP-1/glucagon receptor agonist with FDA Breakthrough Therapy designation for MASH and Priority Review NDA filed February 2026. Phase 3 SYNCHRONIZE-1 reported 16.6% weight loss at 76 weeks; approval possible Q3 2026. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss View Details: https://peptrackerpro.com/peptides/survodutide \+ Compare: https://peptrackerpro.com/compare?select=survodutide Track in App: https://app.peptrackerpro.com/?add=survodutide ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+1 more View Details: https://peptrackerpro.com/peptides/tirzepatide \+ Compare: https://peptrackerpro.com/compare?select=tirzepatide Track in App: https://app.peptrackerpro.com/?add=tirzepatide ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Cagrilintide", "description": "A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026.", "url": "https://peptrackerpro.com/peptides/cagrilintide", "lastReviewed": "2026-06-13", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Cagrilintide", "item": "https://peptrackerpro.com/peptides/cagrilintide" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People researching amylin-based therapies?", "acceptedAnswer": { "@type": "Answer", "text": "Cagrilintide is a research peptide studied in preclinical models. A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026." } }, { "@type": "Question", "name": "Those following CagriSema clinical trials?", "acceptedAnswer": { "@type": "Answer", "text": "Cagrilintide is a research peptide studied in preclinical models. A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026." } }, { "@type": "Question", "name": "Individuals comparing appetite-regulation compounds?", "acceptedAnswer": { "@type": "Answer", "text": "Cagrilintide is a research peptide studied in preclinical models. A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026." } } ] } ] ```